FAIR LAWN, N.J., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Columbia Financial, Inc. (Nasdaq: CLBK) (the “Company”), the mid-tier holding company for Columbia Bank (the “Bank”), announced today that Matthew Smith has been appointed as Senior Executive Vice President and Chief Operating Officer of the Company and the Bank effective as of November 25, 2024. The Company previously disclosed the retirement of E. Thomas Allen, Jr., the current Senior Executive Vice President and Chief Operating Officer of the Company and the Bank, effective as of January 31, 2025. Mr. Smith served as the Chief Digital Banking Officer and Head of Enterprise Product, Marketing and Transformation at Webster Bank from February 2022 until November 2024. Prior to that time, Mr. Smith served as Head of Digital Banking and Banking as a Service at Sterling National Bank from January 2020 to February 2022 (when Sterling National Bank was acquired by Webster Bank) and Chief Product and Marketing Strategy Officer of Sterling National Bank from October 2017 to January 2020. Thomas J. Kemly, President and Chief Executive Officer of the Company and the Bank, said on the appointment: “Matthew has a proven track record of driving innovation and growth in banking operations, and we are pleased to welcome him to the Company and the Bank. We look forward to working with Matthew as part of our executive leadership team in an effort to continue to provide quality and convenient products and services to our customers.” Mr. Kemly continued, “We also extend our deepest appreciation to Tom Allen for his three decades of dedicated service to the Bank. Tom’s expertise and commitment have been instrumental in the continued success of the Company and the Bank and we wish him all the best on his well-deserved retirement.” About Columbia Financial, Inc. Columbia Financial, Inc. is a Delaware corporation organized as Columbia Bank's mid-tier stock holding company. Columbia Financial, Inc. is a majority-owned subsidiary of Columbia Bank, MHC. Columbia Bank is a federally chartered savings bank headquartered in Fair Lawn, New Jersey that operates 68 full-service banking offices and offers traditional financial services to consumers and businesses in its market area. Forward-Looking Statements Certain statements herein constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act and are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by words such as “believes,” “will,” “would,” “expects,” “projects,” “may,” “could,” “developments,” “strategic,” “launching,” “opportunities,” “anticipates,” “estimates,” “intends,” “plans,” “targets” and similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may differ materially from those set forth in the forward-looking statements as a result of numerous factors. Factors that could cause such differences to exist include, but are not limited to, adverse conditions in the capital and debt markets and the impact of such conditions on the Company’s business activities; changes in interest rates, higher inflation and their impact on national and local economic conditions; changes in monetary and fiscal policies of the U.S. Treasury, the Board of Governors of the Federal Reserve System and other governmental entities; the impact of legal, judicial and regulatory proceedings or investigations, competitive pressures from other financial institutions; the effects of general economic conditions on a national basis or in the local markets in which the Company operates, including changes that adversely affect a borrowers’ ability to service and repay the Company’s loans; the effect of acts of terrorism, war or pandemics,, including on our credit quality and business operations, as well as its impact on general economic and financial market conditions; changes in the value of securities in the Company’s portfolio; changes in loan default and charge-off rates; fluctuations in real estate values; the adequacy of loan loss reserves; decreases in deposit levels necessitating increased borrowing to fund loans and securities; legislative changes and changes in government regulation; changes in accounting standards and practices; the risk that goodwill and intangibles recorded in the Company’s consolidated financial statements will become impaired; cyber-attacks, computer viruses and other technological risks that may breach the security of our systems and allow unauthorized access to confidential information; the inability of third party service providers to perform; demand for loans in the Company’s market area; the Company’s ability to attract and maintain deposits and effectively manage liquidity; risks related to the implementation of acquisitions, dispositions, and restructurings; the risk that the Company may not be successful in the implementation of its business strategy, or its integration of acquired financial institutions and businesses, and changes in assumptions used in making such forward-looking statements which are subject to numerous risks and uncertainties, including but not limited to, those set forth in Item 1A of the Company's Annual Report on Form 10-K and those set forth in the Company's Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, all as filed with the Securities and Exchange Commission (the “SEC”), which are available at the SEC’s website, www.sec.gov. Should one or more of these risks materialize or should underlying beliefs or assumptions prove incorrect, the Company's actual results could differ materially from those discussed. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company disclaims any obligation to publicly update or revise any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes, except as required by law. Columbia Financial, Inc. Investor Relations Department (833) 550-0717NEW YORK , Nov. 25, 2024 /PRNewswire/ -- The language training market in india size is estimated to grow by USD 7.55 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 14.37% during the forecast period. Growing emphasis on continuous professional development is driving market growth, with a trend towards integration of technology in learning and training, such as e-learning platforms, virtual reality (VR), and simulations. However, high cost of accessing quality training programs, educational resources, and technology infrastructure poses a challenge. Key market players include Alliance Francaise Paris ile de France , Babbel GmbH, Berlitz Corp., British Council, Cambridge Institute, Cosmolingua, EF Education First Ltd., Georg von Holtzbrinck GmbH and Co. KG, Goethe-Institut, Henry Harvin Education Inc., IFLAC, INaWORD, inlingua International Ltd., Institute of Universal Languages and Education, ITESKUL, IXL Learning Inc., Language Services Bureau, LetsTalk Academy of English and Foreign Languages, Nile, Pearson Plc, ReSOLT EdTech LLP, and Winsome Translators Pvt. Ltd., Alliance Francaise Paris ile de France , Winsome Translators Pvt. Ltd., Apex Language Academy, Bharatiya Vidya Bhavan, Chandigarh Language Academy, Diploma in Foreign Languages, English and Foreign Languages University, Foreign Language Learning Pvt. Ltd., Language Training Institute, and India International Language Academy AI-Powered Market Evolution Insights. Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View Free Sample Report PDF Key Market Trends Fueling Growth The language training market in India has experienced significant growth due to advanced technology integration. E-learning platforms like Babbel offer personalized learning paths and multimedia content. VR technology provides language practice experiences. Simulations offer practical learning scenarios for real-life language use. Institutions use digital language resources and language lab systems for comprehensive learning. These factors increase demand for language training, driving market growth. The Language Training Market in India is experiencing significant growth, with a growth in demand for proficiency in various languages. Skills like Spanish, French, German, Chinese, and Japanese are in high demand. Companies are looking for employees with multilingual skills to cater to their global clientele. E-learning platforms are playing a crucial role in making language training more accessible and affordable. Chatbots and virtual assistants are also being used to enhance the learning experience. The use of technology is transforming the way language training is delivered in India . The trend is towards more interactive and personalized learning methods. The future looks bright for the language training industry in India. Insights on how AI is driving innovation, efficiency, and market growth- Request Sample! Market Challenges The cost of accessing quality language training programs, educational resources, and technology infrastructure in India is a significant barrier to growth in the language training market. Individuals and organizations face financial constraints that limit access to valuable learning opportunities, particularly for those from economically disadvantaged backgrounds or in remote areas. Language learning course fees range from USD120 to USD421 , and the high cost of online courses, study materials, and technology infrastructure can present significant financial hurdles. In rural areas, the lack of reliable internet connectivity and modern computing equipment further exacerbates the challenges of engaging in e-learning and virtual training. These factors are expected to hinder the growth of the language training market in India during the forecast period. The Language Training Market in India faces several challenges. One key challenge is the need to cater to a diverse population with various languages and dialects. Another challenge is the competition from free online resources and low-cost alternatives. Additionally, the lack of standardized curriculum and certification programs can make it difficult for institutions to differentiate themselves. Furthermore, the high cost of quality education and the need for flexible learning options can deter potential students. Lastly, the digital transformation requires language training providers to adapt to e-learning platforms and incorporate technology into their offerings. Insights into how AI is reshaping industries and driving growth- Download a Sample Report Segment Overview This language training market in India report extensively covers market segmentation by 1.1 Institutional learners 1.2 Individual learners 2.1 Classroom-based 2.2 Online 2.3 Blended 3.1 English 3.2 French 3.3 German 3.4 Spanish 3.5 Others 4.1 APAC 1.1 Institutional learners- The language training market in India serves a substantial group of learners in academic institutions, vocational centers, and corporations. These learners aim to boost their language abilities for academic, professional, and personal reasons. In academia, universities like JNU and EFLU provide specialized language courses for students and educators. Vocational training centers, such as NITHM, offer language programs for those entering industries like tourism and international trade. Corporate initiatives, including Wipro, Infosys, and Deloitte, provide language training for professional growth and intercultural communication. Digital language learning platforms, like Coursera for Campus and Rosetta Stone for Enterprise, cater to the unique needs of academic institutions, vocational centers, and corporations. These factors are driving the demand for language training among institutional learners in India . Download complimentary Sample Report to gain insights into AI's impact on market dynamics, emerging trends, and future opportunities- including forecast (2024-2028) and historic data (2018 - 2022) Research Analysis The Language Training Market in India is experiencing significant growth due to the increasing demand for multilingual talent in multinational firms. Specialized courses in E-learning platforms are becoming increasingly popular, offering flexibility and affordability. Artificial Intelligence (AI) integration, through speech recognition and chatbot assistance, is revolutionizing language education. Qualified language instructors provide in-person tutoring to address linguistic gaps. Flexible pricing models cater to various budgets. AI-powered social robots are also being used to enhance language learning experiences. Language start-ups are emerging, offering innovative solutions in digital tutoring for English, Spanish, Chinese, French, German, Japanese, and Korean. Market Research Overview The Language Training Market in India is experiencing significant growth due to the increasing globalization and the rising demand for multilingual workforce. The market caters to various sectors such as BPOs, KPOs, IT, and education. English language training holds the largest market share, followed by other languages like French, German, Spanish, and Chinese. The market is driven by factors such as increasing foreign investments, growing tourism industry, and the need for effective communication in international business. The Indian government and several educational institutions are also promoting language training through various initiatives. The market is expected to continue its growth trajectory in the coming years. Table of Contents: 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation End-user Institutional Learners Individual Learners Learning Method Classroom-based Online Blended Language English French German Spanish Others Business Model ( B2B, B2C, and B2G) Geography APAC 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: www.technavio.com/ SOURCE Technavio
Ghana has rolled out an upgraded version of its passport which is embedded with a microprocessor chip containing the holder’s biometric data. The country’s President Nana Akufo-Addo launched the new travel document at a ceremony in Accra on December 2, to Ghana Broadcasting Corporation. He called the project one of the hallmarks of the country’s digital transformation and modernization efforts led by Vice President Mahamudu Bawumia, noting that the redesigned travel credential comes with enhanced features for improved security and ease of travel. The new passport project is handled by local company Biometric Travel Solutions Ltd under a Build-Operate and Transfer arrangement. This company, which is an official partner of the Foreign Ministry, will work with Hungarian security printing firm ANY Security Printing Company Plc for the next 10 years. “The e-Passport is not just a travel document; it is a symbol of our progress, resilience, and readiness to embrace the future with confidence. This achievement underscores the strategic importance of public-private partnerships in driving national development,” the outlet quotes the president as saying. Akufo-Addo added that the move is part of an ongoing process to digitize and streamline administrative process and ease access to public services. The document is also designed with elements that represent key Ghanaian values, symbols and culture. Foreign Affairs Minister Shirley Ayorkor Botchwey, who also spoke during the launching ceremony, emphasized the security advantages of the new passport, saying it will curb identity theft and make tampering difficult. Beyond security, the minister said the new document has been designed in such a way as to reduce the turn-around time needed to obtain it. She said other measures are also being take to facilitate the application process for the passport. Botchwey said the transition to an upgraded passport underscores not only the government’s quest for efficiency, but also the need to align with international standards in the domain of travel documents prescribed by the International Civil Aviation Organisation (ICAO). “The Government of Ghana has been working assiduously to make its digitization agenda, under the able leadership of the Vice President, a reality through various initiatives. The chip-embedded passport that we are launching today is a major milestone in this journey and boasts of several state-of-the-art features carefully designed to enhance its security and facilitate ease of travel for Ghanaian citizens,” said Botchwey as cited by . “By the introduction of the chip-embedded passport, Ghana is poised to be at the forefront of modern technology within the African sub-region, shortening the turn-around time for passport issuance, while making travel safer, and more secure for all citizens.” As part of its digital transformation drive, Ghana in October to facilitate access to digital government services. | | | | | | |Sir Keir Starmer was speaking at the Joint Expeditionary Force (JEF) conference in Estonia where he met leaders of other Baltic states. After signing an energy partnership with Norwegian Prime Minister Jonas Gahr Store in Bergen, Sir Keir flew to Estonia where he spoke alongside Mr Store and their Estonian counterpart Kristen Michal. Asked what else could be done to support Ukraine, Sir Keir said: “There is an ever-increasing demand for more capability. That is understandable, and Ukraine needs all the capability that it can get, so I think all of us have put in more capability into Ukraine by way of equipment.” He added: “A lot of money has been raised, funding has been raised, but more is going to be needed.” The Prime Minister’s also discussed making the economic case at home for continued support for Ukraine. Sir Keir said: “Making the case on the significance of Ukraine, making the case, to double down, linking it back to each of our countries – what does it mean for us if Russia succeeds, is a really important question that we have to answer with our people to make it clear why it is that we are so supportive of Ukraine, why it is that we must stand with our allies on this, why it is we must make sure that Nato is put in the strongest position as well. “Now, this is a different world to the world of 10, 20 years ago, to recognise the world that we are living in, there’s a positive case as well to be made. “Defence spending doesn’t sort of sit in a silo over here with no effect on the rest of the economy, no effect on technology. “It has a huge effect on technologies, the cutting edge of technology and change which can then be used in other areas. “It binds countries together. I think all of us have got joint projects on in terms of defence capabilities that bind us together. There’s a huge number of well-paid jobs that are very important to our economy in defence spending as well. “But we have to make that positive case. I don’t personally feel that we can sort of sit back and assume that all of those in our respective countries necessarily accept all of our arguments unless we make them in that positive way, which I do think the argument can and should and must be made. “But the challenge that you put to us is the right challenge, which is it’s very difficult when finances are tight, as they are in all of our countries.” On Tuesday morning the Prime Minister will meet Taavi Madiberk, the founder of Estonian tech start-up manufacturing low-cost air defence missiles, Frankenburg Technologies, which is planning to open a new office in London Specialising in the manufacture of the missiles, the rapidly growing company already collaborates closely with the UK defence industry, sourcing a significant portion of its subsystems locally, including from propulsion specialists Roxel in Worcestershire. The Prime Minister will again attend the JEF summit, joining leaders from the Nordics and Baltics to discuss support for Ukraine, the sustained threat posed by Russia and wider European security. He will then visit British forces serving in the region to deter malign Russian threats.
Every American, whether Republican or Democrat, gets an image in their heads when they hear the phrase "childless cat lady." The ornery, wild-haired crone. The dilapidated house and overgrown weeds. The outdated, peeling wallpaper and dusty cookbooks. Boxes of broken and mismatched bric-a-brac, their existence long since forgotten until a naïve caretaker suggests she throw it out, at which time she furiously declares it a priceless treasure. Advertisement And cats. Everywhere, cats. Pampered cats and emaciated cats. Purchased cats and stray cats, vaccinated cats and feral cats, live cats and dead cats. And cat hair. And opened cans of cat food. And cat waste. On the carpet. On the furniture. On the bed. On the countertops. Such is the fantasy of code enforcement officers the nation over. But when the media dug up an old clip of J.D. Vance criticizing "childless cat ladies," the Left collapsed into its usual, predictable hysterics. USA Today chummed the waters and found plenty of grievance studies professors and abortion activists who claimed Vance is "absolutely terrified of the power of American women" and intends to "keep women barefoot, pregnant, and in the kitchen with no human rights." His comment was intentionally misrepresented as an attack on women (and couples) unable to have kids, who adopt kids, or who can't afford kids. But anyone who listened to his complete sentence would not have derived any of this. He also criticized corporate oligarchs, but the Left wasn't going to let that get in the way of a good ol' edited soundbite. Vance's criticism of "childless cat ladies" was that people who willingly choose to not have children for selfish reasons are detrimental to the advancement and continuation of our society. And he's right, for two reasons. First, you know all those economically illiterate entitlement programs you progressives assume as your birthrights? Social Security and Medicare and Obamacare and all that? Well, guess what we need to keep... C.A. SkeetSharks make roster moves ahead of game vs. L.A. KingsNone
LAS VEGAS , Dec. 16, 2024 /PRNewswire/ -- CTLA-4 inhibitors are a well-established market in cancer care, and they are expected to grow significantly in the coming years. This is due to the expected label expansion and usage of the blockbuster YERVOY and an increasing number of new clinical studies evaluating better-acting versions of CTLA-4 inhibitors in various types of cancers. Other market drivers include increased usage of CTLA-4 inhibitors in combination with other immune checkpoint inhibitors and the increasing prevalence of cancer cases. DelveInsight's CTLA-4 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging CTLA-4 inhibitors, market share of individual therapies, and current and forecasted CTLA-4 inhibitors market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany , France , Italy , and Spain ), the United Kingdom , and Japan ]. Key Takeaways from the CTLA-4 Inhibitors Market Report As per DelveInsight's analysis, the total market size of CTLA-4 inhibitors in the 7MM is expected to surge significantly by 2034. In 2023, YERVOY registered global sales of more than USD 2 billion , followed by IMJUDO which closed 2023 with more than USD 200 million in global sales. YERVOY in combination with OPDIVO is approved for multiple indications in first-line settings including metastatic Melanoma, mesothelioma, Renal Cell Carcinoma, NSCLC, Esophageal cancer, Gastric Cancer, and other second-line indications. There are other newer indications where the combo is being evaluated. Established CTLA-4 inhibitor companies include Bristol Myers Squibb (BMS) and AstraZeneca, Leading emerging CTLA-4 inhibitor companies such as Merck , Xilio therapeutics, BioNTech, Agenus, Bioatla OncoC4, and others are developing novel CTLA-4 inhibitors that can be available in the CTLA-4 inhibitors market in the coming years. Some of the key CTLA-4 inhibitors in the pipeline include Quavonlimab (MK-1308), gotistobart ( ONC-392/BN316 ), BA3071 , and others. Discover which therapies are expected to grab the CTLA-4 inhibitors market share @ CTLA-4 Inhibitors Market Report CTLA-4 Inhibitors Market Dynamics In recent years, the CTLA-4 inhibitors market has been shaped by significant advances in cancer immunotherapy. The growing use of combination therapies , particularly the pairing of CTLA-4 inhibitors with PD-1/PD-L1 inhibitors (like nivolumab or pembrolizumab), has transformed the treatment landscape for several cancers, including melanoma, renal cell carcinoma, and non-small cell lung cancer (NSCLC). This combination approach has demonstrated improved survival benefits , broadening the market for CTLA-4 inhibitors beyond their original monotherapy applications. Additionally, research is ongoing to explore the use of these drugs in other cancers such as colorectal and pancreatic cancer, further fueling market growth. However, market dynamics are influenced by several factors, including the high cost of immunotherapy treatments and the side effects associated with CTLA-4 inhibitors . Immune-related adverse events (irAEs) like colitis, hepatitis, and dermatitis are common due to the drug's effect of ramping up immune activity. As a result, healthcare providers are cautious in prescribing these treatments , and pharmaceutical companies are working on optimizing dosing regimens and exploring biomarkers that could predict which patients will respond best to CTLA-4 inhibition. These considerations impact pricing, regulatory approval, and overall market uptake. The competitive landscape is also heating up as more pharmaceutical companies enter the immunotherapy space. While Bristol- Myers Squibb's ipilimumab has dominated the market, new players and biosimilars are emerging. Additionally, research into next-generation CTLA-4 inhibitors and alternative immune checkpoint targets (like LAG-3 and TIGIT) could change the market dynamics further. The evolution and improvisation of this class can be seen through the development of Fc-enhanced tumor-activated anti-CTLA-4 inhibitors (Xilio's Therapeutics' Vilastobart) which also deplete regulatory T cells when activated (unmasked) in the tumor microenvironment (TME). The innovations in drug delivery and therapeutic combinations , is likely to drive new developments in this area, attracting substantial investment and strategic partnerships. Overall, the CTLA-4 inhibitors market remains highly promising, buoyed by the increasing global burden of cancer , the expanding role of immunotherapy in oncology, and the significant unmet need in the treatment of several aggressive cancers. Advances in research and clinical trials , along with ongoing regulatory approvals, are expected to keep this market growing in the foreseeable future. However, balancing efficacy, safety, and cost will be critical for both pharmaceutical companies and healthcare providers to ensure the sustained success of CTLA-4 inhibitors. CTLA-4 Inhibitors Treatment Market Approved CTLA-4 inhibitors at present are YERVOY (ipilimumab) and IMJUDO (tremelimumab-actl). In March 2011 , YERVOY was the first cancer immunotherapy approved for melanoma, specifically targeting CTLA-4. At that time, it was the only approved treatment for unresectable or metastatic melanoma that showed a significant enhancement in overall survival. The FDA's approval of YERVOY represents the result of over 14 years of research and development by BMS teams, as well as clinical trials involving 676 patients with unresectable or metastatic melanoma who had previously received one or more treatments, including aldesleukin, dacarbazine, temozolomide, fotemustine, or carboplatin, in a randomized Phase III clinical trial. IMJUDO is a human monoclonal antibody designed to inhibit the activity of CTLA-4. By blocking CTLA-4, it promotes T-cell activation, which enhances the immune response against cancer and encourages the destruction of cancer cells. With its initial regulatory approval, patients in the US suffering from unresectable liver cancer now have access to an approved dual immunotherapy treatment regimen that uniquely combines CTLA-4 inhibition with a PD-L1 inhibitor, thereby amplifying the immune response to their cancer. YERVOY currently leads the CTLA-4 inhibitor market, generating over USD 2 billion in sales in 2023, while IMJUDO ended the year with sales exceeding USD 200 million . However, numerous CTLA-4 inhibitors are in clinical trials, with some utilizing innovative proprietary technologies in their development, which could pose a significant challenge to YERVOY's market dominance in the future. Learn more about the FDA-approved CTLA-4 inhibitors @ CTLA-4 Inhibitors Drugs Key Emerging CTLA-4 Inhibitors and Companies Several key emerging players, including Merck, BioNTech, Agenus, BioAtla , and others, are involved in developing drugs for CTLA-4 inhibitors for various indications such as metastatic castration-resistant prostate cancer, breast cancer, cervical cancer, non-squamous cell lung cancer, and others. OncoC4/BioNTech's BNT316/ONC-392 (gotistobart) is a next-generation anti-CTLA-4 antibody being co-developed by BioNTech and OncoC4. It is in late-stage clinical trials, either as a monotherapy or in combination with other treatments, targeting various cancers including non-small cell lung cancer, ovarian cancer, high-grade serous adenocarcinoma of the ovary, primary peritoneal carcinoma, and fallopian tube cancer. CTLA-4 is an immune checkpoint receptor that suppresses T cell responses, limiting their ability to identify and destroy cancer cells. Gotistobart is designed to counteract this suppression while maintaining CTLA-4 recycling, which helps preserve T cell immunosuppressive function in peripheral tissues. This approach, now under clinical evaluation, aims to reduce immune-related side effects. BioAtla's BA3071 is a conditionally active biologic (CAB) anti-CTLA-4 antibody being developed as an immuno-oncology agent. It aims to provide efficacy comparable to existing anti-CTLA-4 antibodies, but with reduced toxicity due to its selective activity in the tumor microenvironment. While blocking CTLA-4 has been shown to enhance antitumor responses, it can also cause immune-related damage to healthy cells. To reduce this risk of on-target, off-tumor effects, BioAtla has used its proprietary CAB technology to ensure that BA3071 binds to the CTLA-4 receptor only on T cells within the tumor microenvironment. This design is intended to enhance both the efficacy and safety of anti-CTLA-4 therapy, whether used alone or in combination with other treatments, by activating T cells specifically in the tumor site. BA3071 is currently in Phase II trials for treating various solid tumors that respond to CTLA-4 inhibition in combination with a PD-1 blocking agent. The anticipated launch of these emerging therapies are poised to transform the CTLA-4 inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the CTLA-4 inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about CTLA-4 inhibitors clinical trials, visit @ CTLA-4 Inhibitors Treatment Drugs CTLA-4 Inhibitors Overview CTLA-4 inhibitors are a class of immune checkpoint inhibitors that target cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), a protein expressed in T cells. CTLA-4 plays a crucial role in downregulating immune responses by binding to B7 molecules on antigen-presenting cells (APCs), which suppresses T-cell activation. By inhibiting CTLA-4, these drugs block the suppression of T cells, thereby enhancing the immune system's ability to recognize and destroy cancer cells. This mechanism has made CTLA-4 inhibitors an essential part of cancer immunotherapy, particularly in treating advanced-stage malignancies like melanoma. Ipilimumab, the first approved CTLA-4 inhibitor, has shown significant survival benefits in clinical trials, leading to its use in combination with other immune checkpoint inhibitors, such as PD-1 inhibitors, to further improve patient outcomes. While CTLA-4 inhibitors have shown promise in cancer therapy, their use comes with challenges, particularly immune-related adverse events (irAEs). These adverse effects occur because the inhibition of CTLA-4 can lead to excessive immune activation, which may result in the immune system attacking normal tissues and organs. Common irAEs include colitis, dermatitis, and hepatitis. Managing these side effects requires a delicate balance between maintaining the anti-cancer immune response and mitigating harmful autoimmune reactions. Despite these challenges, the clinical benefits of CTLA-4 inhibitors have made them a vital component in the fight against cancer, driving ongoing research into their optimization and use in combination therapies. CTLA-4 Inhibitors Report Metrics Details Study Period 2020–2034 CTLA-4 Inhibitors Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key CTLA-4 Inhibitors Companies Bristol Myers Squibb, AstraZeneca, Merck, Xilio therapeutics, BioNTech, Agenus, Bioatla OncoC4, Aadageneand others Key CTLA-4 Inhibitors YERVOY,IMJUDO, Quavonlimab, ONC-392/BN316 (gotistobart), BA3071, and others Scope of the CTLA-4 Inhibitors Market Report CTLA-4 Inhibitors Therapeutic Assessment: CTLA-4 Inhibitors current marketed and emerging therapies CTLA-4 Inhibitors Market Dynamics: Conjoint Analysis of Emerging CTLA-4 Inhibitors Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, CTLA-4 Inhibitors Market Access and Reimbursement Discover more about CTLA-4 inhibitors in development @ CTLA-4 Inhibitors Clinical Trials Table of Contents 1 Key Insights 2 Report Introduction 3 Key Highlights 4 Executive Summary of CTLA-4 Inhibitor 5 Key Events 6 Target Addressable Pool and Market Forecast Methodology 7 CTLA-4 Inhibitor Market Overview at a Glance in the 7MM 7.1 Market Share (%) Distribution by Therapies in 2023 7.2 Market Share (%) Distribution by Therapies in 2034 8 Background and Overview 8.1 Introduction 8.2 Treatment 9 Target Patient Pool 9.1 Key Findings 9.2 Assumptions and Rationale: 7MM 9.3 Epidemiology Scenario in the 7MM 9.3.1 Total Cases in Selected Indications for CTLA-4 Inhibitor in the 7MM 9.3.2 Total Eligible Patient Pool for CTLA-4 Inhibitor in Selected Indications in the 7MM 9.3.3 Total Treated Cases in Selected Indications for CTLA-4 Inhibitor in the 7MM 10 Marketed Drugs 10.1 Key Competitors 10.2 YERVOY: Bristol Myers and Squibb (BMS) 10.2.1 Product description 10.2.2 Regulatory milestones 10.2.3 Other development activities 10.2.3.1 Clinical development 10.2.4 Safety and efficacy 10.3 IMJUDO: Astrazeneca 10.3.1 Product description 10.3.2 Regulatory milestones 10.3.3 Other development activities 10.3.3.1 Clinical development 10.3.4 Safety and efficacy 11 Emerging Therapies 11.1 Key Competitors 11.2 Quavonlimab: Merck 11.2.1 Product description 11.2.2 Other developmental activities 11.2.3 Clinical development 11.2.4 Safety and efficacy 11.3 Vilastobart: Xilio therapeutics 11.3.1 Product description 11.3.2 Other developmental activities 11.3.3 Clinical development 11.3.4 Safety and efficacy 11.4 BA3071: BioAtla 11.4.1 Product description 11.4.2 Other developmental activities 11.4.3 Clinical development 11.4.4 Safety and efficacy *List to be continued in the report 12 CTLA-4 Inhibitor: 7MM analysis 12.1 Key Findings 12.2 Market Outlook 12.3 Conjoint Analysis 12.4 Key Market Forecast Assumptions 12.4.1 Cost Assumptions and Rebates 12.4.2 Pricing Trends 12.4.3 Analogue Assessment 12.4.4 Launch Year and Therapy Uptakes 12.5 United States Market Size 12.5.1 Market Size by Indications in the US 12.5.2 Market Size by Therapies in the US 12.6 EU4 and the UK Market Size 12.6.1 Market Size by Indications in EU4 and the UK 12.6.2 Market Size by Therapies in EU4 and the UK 12.7 Japan Market Size 12.7.1 Market Size by Indications in Japan 12.7.2 Market Size by Therapies in Japan 13 Unmet Needs 14 SWOT Analysis 15 KOL Views 16 Market Access and Reimbursement 17 Appendix 17.1 Bibliography 17.2 Report Methodology 18 DelveInsight Capabilities 19 Disclaimer 20 About DelveInsight Related Reports Non-small Cell Lung Cancer Market Non-small Cell Lung Cancer Market Insight, Epidemiology and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including EMD Serono, Merck, Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies, Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb, Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen, Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo, Inc., AstraZeneca, Precision Biologics, Inc, Promontory Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals, Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance Biotherapeutics, Inc., Innate Pharma , among others. Non-small Cell Lung Cancer Pipeline Non-small Cell Lung Cancer Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-small cell lung cancer companies, including BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, BridgeBio Pharma, Abbvie, Pfizer, Eli Lilly and Company BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang , Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical, Pierre Fabre , Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, among others. Ovarian Cancer Market Ovarian Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key ovarian cancer companies including Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co, Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, VBL Therapeutics, AbbVie, Elevation oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics , among others. Ovarian Cancer Pipeline Ovarian Cancer Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ovarian cancer companies, including Gradalis, VBL Therapeutics, AbbVie, Elevation oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur info@delveinsight.com +14699457679 Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpgNone
This cult comedian is touring in March. She still has no idea what her act will bePep Guardiola denies rumours of a rift with Kevin De Bruyne
Pep Guardiola denies rumours of a rift with Kevin De Bruyne
YPSILANTI, Mich. (AP) — On a damp Wednesday night with temperatures dipping into the 30s, fans in sparsely filled stands bundled up to watch Buffalo beat Eastern Michigan 37-30 on gray turf. The lopsided game was not particularly notable, but it was played on one of the nights the Mid-American Conference has made its own: A weeknight. “A lot of the general public thinks we play all of our games on Tuesdays and Wednesdays, not just some of them in November,” MAC Commissioner Jon Steinbrecher said in a telephone interview this week. “What it has done is help take what was a pretty darned good regional conference and has given it a national brand and made it a national conference.” When the conference has played football games on ESPN or ESPN2 over the last two seasons, the linear television audience has been 10 times larger than when conference schools meet on Saturdays and get lost in the shuffle when viewers have many more choices. The most-watched MAC game over the last two years was earlier this month on a Wednesday night when Northern Illinois won at Western Michigan and there were 441,600 viewers, a total that doesn’t include streaming that isn’t captured by Nielsen company. During the same span, the linear TV audience has been no larger than 46,100 to watch two MAC teams play on Saturdays. “Having the whole nation watching on Tuesday and Wednesday night is a huge deal for the MAC,” Eastern Michigan tight end Jere Getzinger said. “Everybody wants to watch football so if you put it on TV on a Tuesday or Wednesday, people are going to watch.” ESPN has carried midweek MAC football games since the start of the century. ESPN and the conference signed a 13-year extension a decade ago that extends their relationship through at least the 2026-27 season. The conference has made the most of the opportunities, using MACtion as a tag on social media for more than a decade and it has become a catchy marketing term for the Group of Five football programs that usually operate under the radar in Michigan, Ohio, Indiana, Illinois and New York. Attendance does tend to go down with weeknight games, keeping some students out of stadiums because they have class or homework and leading to adults staying away home because they have to work the next morning. “The tradeoff is the national exposure,” Buffalo coach Pete Lembo said. “You know November nights midweek the average fan is going to park on the couch, have a bowl of chips and salsa out in front, and watch the game from there." When the Bulls beat Ball State 51-48 in an overtime thriller on a Tuesday night earlier this month, the announced attendance was 12,708 and that appeared to be generous. There were many empty seats after halftime. “You watch the games on TV, the stadiums all look like this,” Buffalo fan Jeff Wojcicki said. “They are not packed, but it’s the only game on, and you know where to find it.” Sleep and practice schedules take a hit as well, creating another wave of challenges for students to attend class and coaches to prepare without the usual rhythm of preparing all week to play on Saturday. “Last week when we played at Ohio in Athens, we had a 4-four bus ride home and got home at about 3:30 a.m.,” Eastern Michigan center Broderick Roman said. “We still had to go to class and that was tough, but it's part of what you commit to as an athlete.” That happens a lot in November when the MAC shifts its unique schedule. During the first two weeks of the month, the conference had 10 games on Tuesdays and Wednesdays exclusively. This week, there were five games on Tuesday and Wednesday while only one was left in the traditional Saturday slot with Ball State hosting Bowling Green. Next week, Toledo plays at Akron and Kent State visits Buffalo on Tuesday night before the MAC schedule wraps up with games next Friday and Saturday to determine which teams will meet in the conference title game on Dec. 7 in Detroit. In all, MAC teams will end up playing about 75% of their games on a Saturday and the rest on November weeknights. When the Eagles wrapped up practice earlier this week, two days before they played the Bulls, tight end Jere Getzinger provided some insight into the effects of the scheduling quirk. “It's Monday, but for us it's like a Thursday,” he said. Bowling Green coach Scot Loeffler said he frankly has a hard time remembering what day it is when the schedule shift hits in November. “The entire week gets turned upside down,” Loeffler said. “It’s wild, but it’s great for the league because there’s two days a week this time of year that people around the country will watch MAC games.” AP freelance writer Jonah Bronstein contributed to this report. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football
None